Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Left Arrow
    Right Arrow

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designatio...
    MYR Pharma is focused on the development of Myrcludex B, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug targets the protein NTCP on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex B has shown an excellent safety profile and antiviral efficacy in several clinical trials. The drug has received Orphan Designations for the treatment of HDV infection from EMA and FDA. Myrcludex B has been added to a short list of drugs eligible for the PRIME (PRIority MEdicine) scheme by the European Medicines Agency

    List your booth number for exhibitions, ask us